NGN Capital is a venture capital firm specializing in investments in the US and European healthcare sector.
Business Model:
Revenue: $5.8M
Employees: 2-10
Address: 369 Lexington Ave
City: New York
State: NY
Zip: 10017
Country: US
NGN Capital is a venture capital firm specializing in investments in the US and European healthcare sector. The fund focuses specifically on investments in the healthcare, pharmaceutical, and biotech sectors including drug products, medical devices, diagnostics, and healthcare services.
Contact Phone:
+12129720077
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
1/2009 | Vivaldi Biosciences | Series A | 23M |
8/2005 | Sightline Technologies | Series D | 0 |
10/2005 | OptiScan Biomedical | Venture Round | 36M |
7/2017 | Exosome Diagnostics | Series C | 0 |
5/2008 | ACT Biotech | Series A | 6.6M |
3/2006 | EKOS Corporation | Series C | 0 |
1/2007 | Tigris Pharmaceuticals | Series B | 16M |
3/2010 | Valtech Cardio | Series B | 17.8M |
7/2010 | Artisan Pharma | Series C | 0 |
11/2005 | Javelin Pharmaceuticals | Private Equity Round | 32M |
10/2006 | Santhera Pharmaceuticals | Series C | 0 |
2/2005 | Jerini | Venture Round | 20.2M |
1/2016 | Exosome Diagnostics | Series B | 0 |
3/2014 | Exosome Diagnostics | Series B | 0 |
3/2010 | Artisan Pharma | Series B | 22M |
7/2007 | BeneChill | Series B | 3.5M |
11/2013 | Endosense | Series C | 41.2M |
12/2004 | Santhera Pharmaceuticals | Series A | 0 |
9/2006 | Artisan Pharma | Series A | 39M |
4/2009 | Aerovance | Venture Round | 38M |
5/2010 | Noxxon Pharma | Series D | 40.7M |
4/2009 | Small Bone Innovations | Series D | 0 |
11/2012 | Endosense | Series C | 40.3M |
7/2012 | Cerapedics | Series C | 0 |
9/2015 | Exosome Diagnostics | Series B | 0 |
2/2005 | EKOS Corporation | Series B | 0 |
4/2009 | Cerapedics | Series B | 15M |
12/2010 | Small Bone Innovations | Series F | 0 |
1/2008 | Small Bone Innovations | Series C | 0 |
12/2005 | Small Bone Innovations | Series B | 0 |
3/2007 | Aerovance | Series C | 60M |
3/2007 | Nitec Pharma AG | Series B | 26M |
8/2004 | Aerovance | Series B | 32M |
10/2008 | Micromet | Post-IPO Equity | 0 |
5/2010 | Exosome Diagnostics | Series A | 20M |
9/2009 | BeneChill | Series C | 13.5M |
12/2005 | Santhera Pharmaceuticals | Series B | 0 |
1/2014 | PIN Pharma | Series A | 6.8M |
7/2017 | Exosome Diagnostics | Series C | 0 |
1/2016 | Exosome Diagnostics | Series B | 0 |
9/2015 | Exosome Diagnostics | Series B | 0 |
3/2014 | Exosome Diagnostics | Series B | 0 |
1/2014 | PIN Pharma | Series A | 0 |
11/2013 | Endosense | Series C | 0 |
11/2012 | Endosense | Series C | 0 |
7/2012 | Cerapedics | Series C | 0 |
12/2010 | Small Bone Innovations | Series F | 0 |
7/2010 | Artisan Pharma | Series C | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|